VC-Backed Innovators Reach Market Faster Than “Bootstrappers” – NVCA
This article was originally published in The Gray Sheet
Executive Summary
U.S. venture capital investments in heart disease-related technologies have surpassed $22 bil. over the last 20 years, according to a report released by the National Venture Capital Association Dec. 1